Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )
Mr. Ingalls brings over 40 years of financial leadership, including nearly20 years of experience as a chief financial officer to ArunA's Board. Prior tohis current role as CFO of Premier Exhibitions, Mr. Ingalls served as VicePresident and Chief Financial Officer at CardioMEMS, where he played a keyrole in the organization's transformation. During his tenure at CardioMEMS,Mr. Ingalls led the completion of two private financing rounds totaling over$45 million with venture capitalists and strategic investors. From 2001 to2006, he held the position of Vice President of Finance and Chief FinancialOfficer of Serologicals Corporation. Under Mr. Ingalls' leadership,Serologicals' enterprise value increased by nearly $1.0 billion, as the resultof strong organic growth, successful acquisitions and stringent cost control.Prior to his work with Serologicals, Mr. Ingalls was employed as President andChief Financial Officer of LaRoche Industries, Inc. Mr. Ingalls is a memberof the American Institute of Certified Public Accountants and received a BBAdegree in Accounting from the University of Wisconsin.
Advertisement
"We are pleased to welcome Bud to the ArunA Board. His domain knowledgeand impressive combination of strategic and financial expertise in the lifesciences industry will be a tremendous asset to ArunA Biomedical as we moveforward in our next phase of growth," said ArunA President and CEO, William T.Sharp.
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately heldbiotechnology corporation dedicated to the discovery, manufacturing andcommercialization of emerging new technologies in human stem cell research foruse in drug discovery and basic research. ArunA is the first company tocommercialize products derived from human embryonic stem cells and sees itsproprietary technology as a catalyst leading to the discovery of noveltherapeutic compounds, tests for neurotoxicity and breakthroughs inunderstanding human development and diseases.
For more information, visit: www.arunabiomedical.com
SOURCE ArunA Biomedical, Inc.